These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 9439546)

  • 1. Effect of allopurinol and benzbromarone on the concentration of uridine in plasma.
    Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Yamakita J; Higashino K
    Metabolism; 1997 Dec; 46(12):1473-6. PubMed ID: 9439546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.
    Perez-Ruiz F; Alonso-Ruiz A; Calabozo M; Herrero-Beites A; García-Erauskin G; Ruiz-Lucea E
    Ann Rheum Dis; 1998 Sep; 57(9):545-9. PubMed ID: 9849314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
    Reinders MK; Haagsma C; Jansen TL; van Roon EN; Delsing J; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of allopurinol on beer-induced increases in plasma concentrations and urinary excretion of purine bases (uric acid, hypoxanthine, and xanthine).
    Ka T; Moriwaki Y; Inokuchi T; Yamamoto A; Takahashi S; Tsutsumi Z; Yamamoto T
    Horm Metab Res; 2006 Mar; 38(3):188-92. PubMed ID: 16673211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of urate-lowering therapies on renal handling of uric acid.
    Ma L; Wei L; Chen H; Zhang Z; Yu Q; Ji Z; Jiang L
    Clin Rheumatol; 2016 Jan; 35(1):133-41. PubMed ID: 25373449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients.
    Wu J; Zhang YP; Qu Y; Jie LG; Deng JX; Yu QH
    Int J Rheum Dis; 2019 Aug; 22(8):1445-1451. PubMed ID: 31317680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does benzbromarone in therapeutic doses raise renal excretion of oxipurinol?
    Mertz DP; Eichhorn R
    Klin Wochenschr; 1984 Dec; 62(24):1170-2. PubMed ID: 6530890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout.
    Müller FO; Schall R; Groenewoud G; Hundt HK; van der Merwe JC; van Dyk M
    Eur J Clin Pharmacol; 1993; 44(1):69-72. PubMed ID: 8436158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
    Reinders MK; van Roon EN; Jansen TL; Delsing J; Griep EN; Hoekstra M; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.
    Reinders MK; van Roon EN; Houtman PM; Brouwers JR; Jansen TL
    Clin Rheumatol; 2007 Sep; 26(9):1459-65. PubMed ID: 17308859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The influence of allopurinol on purine- and pyrimidinesynthesis (author's transl)].
    Gröbner W; Zöllner N
    Klin Wochenschr; 1978 Mar; 53(16):255-60. PubMed ID: 682520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacology of hypouricemic effect of benzbromarone.
    Sinclair DS; Fox IH
    J Rheumatol; 1975 Dec; 2(4):437-45. PubMed ID: 1206675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma concentrations and urinary excretion of purine bases (uric acid, hypoxanthine, and xanthine) and oxypurinol after rigorous exercise.
    Kaya M; Moriwaki Y; Ka T; Inokuchi T; Yamamoto A; Takahashi S; Tsutsumi Z; Tsuzita J; Oku Y; Yamamoto T
    Metabolism; 2006 Jan; 55(1):103-7. PubMed ID: 16324927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gout due to xanthine derivatives.
    Toda K; Goriki K; Ochiai M; Tokunou H; Uehara S; Takahashi H; Okusaki K
    Br J Rheumatol; 1997 Oct; 36(10):1131-2. PubMed ID: 9374937
    [No Abstract]   [Full Text] [Related]  

  • 15. Excellent response to the clinical treatment of tophaceous gout.
    Caldas CA; Fuller R
    Clin Rheumatol; 2007 Sep; 26(9):1553-5. PubMed ID: 17047891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout.
    Stocker SL; Graham GG; McLachlan AJ; Williams KM; Day RO
    J Rheumatol; 2011 May; 38(5):904-10. PubMed ID: 21285173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia.
    Akkasilpa S; Osiri M; Deesomchok U; Avihingsanon Y
    J Med Assoc Thai; 2004 Sep; 87(9):1087-91. PubMed ID: 15516011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of allopurinol on beer-induced increases in plasma concentrations of purine bases and uridine.
    Inokuchi T; Ka T; Yamamoto A; Takahashi S; Tsutsumi Z; Moriwaki Y; Yamamoto T
    Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):601-3. PubMed ID: 18600512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hyperuricemia and gout--treatment].
    Gröbner W; Walter-Sack I
    Dtsch Med Wochenschr; 2002 Feb; 127(5):210-3. PubMed ID: 11821994
    [No Abstract]   [Full Text] [Related]  

  • 20. Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone.
    Colin JN; Farinotti R; Fredj G; Tod M; Clavel JP; Vignon E; Dietlin F
    Eur J Clin Pharmacol; 1986; 31(1):53-8. PubMed ID: 3780828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.